February 6, 2018 2:55pm

Cash positions … WHO needs to “tap” the capital markets for continued survival? How are enrollments going as to population and are they sustainable re drop-outs? Has the data from on-going trials been construed as to render measureable and definitive outcomes? Is the company partnered to ward-off the issues of dilution and share depreciation! And finally, does the current CEO have the staying power to withstand their past mistakes and take our investments to the next stage – 2018?

Learn who is stumbling and what the mumbling means …


For 8 years, RMi is the only source of actionable intelligence for the stem, cell and gene therapy and regenerative medicine’s universe (SCGT&RM).

You’ve enjoyed complimentary access to unbiased analysis, in-depth analytics, and informational synthesis along with RMi’s exclusive listing of “our” universe’s stocks and their potential for gains and losses; but exclusivity is now here. Access to RegMed Investors’ targeted content will be by subscription only. 


For continued access to what one industry CEO calls the “Bible” for smart investing in the RegMed and cell therapy sector, click on the button below:



.....  Never leave an investor uninformed  .......